Clinical experience of marketed Levetiracetam in an epilepsy clinic—a one year follow up study
Authors:
- Tim BettsTBTim Betts
- Helen YarrowHYHelen Yarrow
- Lyn GreenhillLGLyn Greenhill
- Mary BarrettMBMary Barrett
- 1 April 2003
- journal article
- clinical trial
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 12 (3) , 136-140
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Refractory epilepsy: a progressive, intractable but preventable condition?Seizure: European Journal of Epilepsy, 2002
- Long-term continuation of levetiracetam in patients with refractory epilepsyNeurology, 2001
- Levetiracetam for partial seizuresNeurology, 2000
- Early Identification of Refractory EpilepsyNew England Journal of Medicine, 2000
- Pharmacokinetic profile of levetiracetamPharmacology & Therapeutics, 2000
- Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsyEuropean Journal of Pharmacology, 1998
- The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranesEuropean Journal of Pharmacology, 1995